The calcineurin inhibitor market is estimated to be valued at US$ 10.07 Bn in 2023 and is expected to exhibit a CAGR of 10% over the forecast period 2023 to 2030, as highlighted in a new report published by Coherent Market Insights.
Market Overview:
Calcineurin inhibitors are a class of immunosuppressant drugs that function by inhibiting the phosphatase activity of calcineurin. Calcineurin inhibitors such as cyclosporine and tacrolimus are primarily used to prevent rejection in organ transplant recipients. They are considered the standard treatment for preventing acute rejection in kidney, liver, and heart transplant recipients. They are also used for the treatment of severe psoriasis and atopic dermatitis.
Market Key Trends:
The rise in solid organ transplant procedures such as kidney, liver, and heart transplants is expected to propel the growth of calcineurin inhibitor market over the forecast period. According to the International Society for Heart & Lung Transplantation, over 3,800 heart transplants were performed in the US in 2019. Furthermore, increase in FDA approvals of generic versions of calcineurin inhibitors is anticipated to boost the market growth. For instance, in December 2021, Mylan N.V. received FDA approval for tacrolimus capsules, a generic version of Prograf capsules, indicated for prophylaxis of organ rejection in kidney transplantation. Improved accessibility and affordability of generic versions is expected to increase treatment uptake.
Porter's Analysis
Threat of new entrants: Low capital requirements and existing patents pose barriers for new companies to enter the market.
Bargaining power of buyers: Buyers have moderate bargaining power as there are few alternative treatment options available.
Bargaining power of suppliers: Suppliers have high bargaining power since active pharmaceutical ingredients and key starting materials are specialized.
Threat of new substitutes: Threat of substitutes is moderate as new drugs are still in development and clinical trial phases.
Competitive rivalry: Intense competition exists among existing players.
SWOT Analysis
Strengths: Established efficacy and safety profile of calcineurin inhibitors. Existing large patient pool being treated.
Weaknesses: Require lifelong adherence to medication. Associated with nephrotoxicity and other side effects on long-term use.
Opportunities: Growth opportunities in developing markets. Launch of new delivery formulations.
Threats: Patent expiries opening market for generics. Rising preference for personalized medicine approaches.
Key Takeaways
The Global Calcineurin Inhibitor Market Demand is expected to witness high growth, exhibiting CAGR of 10% over the forecast period, due to increasing prevalence of autoimmune diseases and post-transplant rejection. The US and Germany dominate the market currently due to large patient pool and favorable reimbursement policies.
Regional analysis: Asia Pacific is expected to grow at the fastest rate due to rising healthcare expenditure and increasing medical tourism. China, India, and Japan are major markets in the region. North America will continue to hold the largest share due to repetitive prescriptions for transplant patients and large transplantation procedures volume.
Key players operating in the calcineurin inhibitor market are Novartis AG, Astellas Pharma Inc., LEO Pharma A/S, Allergan, Inc., Pfizer Inc., Sanofi SA, GlaxoSmithKline plc, Johnson & Johnson Services, Inc., Merck & Co., Inc., Roche Holding AG, Bristol Myers Squibb Company, AbbVie Inc., Eli Lilly and Company, Takeda Pharmaceutical Company Limited, and Mylan N.V.
Read More:
https://www.pressreleasebulletin.com/calcineurin-inhibitor-market-growth-insights-and-trends/
The Enzyme Inhibitor market research report provides the latest industry data, growth, key segments and future trends on the basis of the detailed study.
This market report also allows you to identify the future opportunity and growth rate of the leading segment based on regions and countries.The report also covers detailed competitive landscape including company profiles of key players operating in the global market.
The key players in the enzyme inhibitor market include Abbott Laboratories Inc., AstraZeneca, Bayer, GlaxoSmithKline, Johnson & Johnson, Novartis, Ranbaxy Laboratories, Roche & Pfizer and Takeda among others.
An in-depth view of the competitive outlook includes future capacities, key mergers & acquisitions, financial overview, partnerships, collaborations, new product launches, new product developments and other developments with information in terms of H.Q.Get more information on "Global Enzyme Inhibitor Market Research Report" by requesting FREE Sample Copy at https://www.valuemarketresearch.com/contact/enzyme-inhibitor-market/download-sampleMarket DynamicsThe growing prevalence of cardiovascular disease, gastrointestinal disease, hepatitis, cancer, diabetes and other chronic medical conditions is driving the market growth.
This detailed market study is centered on the data obtained from multiple sources and is analyzed using numerous tools including porter’s five forces analysis, market attractiveness analysis and value chain analysis.
These tools are employed to gain insights of the potential value of the market facilitating the business strategists with the latest growth opportunities.
